Myrle’s Story

At 79 years old, Myrle is not your typical senior. She retired from the financial planning business at 74. After three years of volunteer work, she decided to dive back into the job market, joining Prosperity Mortgage, a Wells Fargo joint venture, at the age of 77. The job had Myrle traveling throughout Delaware and nearby New Jersey and Pennsylvania, counseling other senior citizens about reverse mortgages.

It was during this time, the fall of 2009, that Myrle started experiencing extremely painful headaches. Myrle has suffered from migraines all her life, but these headaches were different. She paid a visit to her doctor who suggested she get an MRI. The MRI revealed a tumor, a meningioma, located in her brain.

Myrle had a few options. She could undergo conventional surgery, but surgery carried some major risks including seizures and vision problems. She could also take the wait-and-see approach, but leaving the tumor untreated made Myrle uneasy. So she decided to undergo treatment using the CyberKnife® Robotic Radiosurgery System.

This outpatient, non-invasive procedure uses targeted beams of radiation to destroy tumors. CyberKnife radiosurgery would allow for the doctors to deliver the radiation to Myrle’s tumor while avoiding her normal brain tissue to minimize the chance of side effects. Myrle underwent three, half-hour CyberKnife treatments in August 2009.

“It was relaxing,” said Myrle. “I just laid on the table and listened to some nice music while the technicians kept track of my treatment.”

Myrle didn’t experience any side effects during her treatments. After each treatment, she left the hospital and went about her usual day, never missing a beat.

As of Jan. 2011, Myrle’s tumor is stable. It hasn’t grown, and her doctors expect it will begin to shrink over time. She no longer experiences those excruciating headaches and has been able to focus on her active life.

After a year of consulting and being on the road, Myrle decided to take a break and become a freelance writer. She spends her time reporting for a Delaware magazine aimed at seniors and writing white papers, grant proposals, and website content for local businesses. In her spare time, Myrle hopes to start her first novel.

As of the creation of this patient profile, Myrle found her CyberKnife treatment to be successful.

Share Your Story

Educating others about your experience with the CyberKnife® System can help others who face similar decisions about their own cancer treatment choices.

If you are interested in sharing your story, please fill out the form below and an Accuray representative will contact you.

Please note: Accuray is the manufacturer of the CyberKnife®, TomoTherapy®, and Radixact® Systems. As the manufacturer, we are unable to provide specific medical advice, view medical records, or schedule appointments.
Privacy Disclaimer: To protect your safety, please do not provide your personal or sensitive information, such as your medical history, on our websites. By entering any information on our websites, you understand and agree that such information will be transferred to Accuray Incorporated in the United States. Please read our Privacy Policy.
Important Safety Statement: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient’s general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.